Strategy & Commercialization

Challenge: An AI-driven drug discovery company requested an expert third party assessment of the attractiveness and risks of a particular discovery strategy focused on a dual tyrosine kinase...

Challenge: A mid-sized pharmaceutical company was considering the option of expanding into developing gene therapies for CNS diseases. Alacrita was asked to help them evaluate and prioritize the...

Challenge A company had developed a technology for overcoming solubility issues in drug formulations and was planning to develop a small number of 505 (b)(2) candidate molecules. The client had...

Challenge A European clinical-stage biopharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy....

Challenge A European investor was refocusing its investment efforts and considering targeting the oncology cell therapy space. It had a particular interest in tumor infiltrating lymphocytes (TILs)...

Challenge A pharma investor client joined a European animal health company and asked Alacrita to conduct a strategic review, in the light of urgent business needs. The entire sector had been through...

Challenge: A private venture-backed US biotech company was developing a biologic through late-stage drug discovery and wished to quantify the commercial opportunity for the product in treating anemia...

Challenge: A national biomedical research agency requested Alacrita’s support with (1) a technical assessment of the agency’s own internal capabilities in AAV manufacturing, (2) a global landscape of...

Challenge: A US-based biotech company developing a novel biologic which impacts iron metabolism, wanted help deciding which disease and patient groups would make the best lead indication for...

Challenge: A university spinout was developing oligonucleotide therapeutics to address age-related disorders. The company wanted to understand the most attractive lead indications in which to focus...

Challenge Alacrita supported the European arm of a major company creation investor as part of an ongoing workstream to evaluate the benefits of refocusing its investments into the tumour infiltrating...

Challenge: For a university with an early stage novel inhibitor of the JAK2/STAT5 pathway intended to treat hematologic malignancies, Alacrita was asked to validate a development plan to support...